These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28885261)

  • 1. Epigenetic Alterations in Bone and Soft Tissue Tumors.
    Wojcik J; Cooper K
    Adv Anat Pathol; 2017 Nov; 24(6):362-371. PubMed ID: 28885261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities.
    McBride MJ; Kadoch C
    J Pathol; 2018 Apr; 244(5):638-649. PubMed ID: 29359803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hereditary SWI/SNF complex deficiency syndromes.
    Agaimy A; Foulkes WD
    Semin Diagn Pathol; 2018 May; 35(3):193-198. PubMed ID: 29397238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromatin regulators with tumor suppressor properties and their alterations in human cancers.
    Shu XS; Li L; Tao Q
    Epigenomics; 2012 Oct; 4(5):537-49. PubMed ID: 23130835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation.
    Wang X; Lee RS; Alver BH; Haswell JR; Wang S; Mieczkowski J; Drier Y; Gillespie SM; Archer TC; Wu JN; Tzvetkov EP; Troisi EC; Pomeroy SL; Biegel JA; Tolstorukov MY; Bernstein BE; Park PJ; Roberts CW
    Nat Genet; 2017 Feb; 49(2):289-295. PubMed ID: 27941797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
    Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
    Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromatin remodeler mutations in human cancers: epigenetic implications.
    Skulte KA; Phan L; Clark SJ; Taberlay PC
    Epigenomics; 2014; 6(4):397-414. PubMed ID: 25333849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Driver mutations of cancer epigenomes.
    Roy DM; Walsh LA; Chan TA
    Protein Cell; 2014 Apr; 5(4):265-96. PubMed ID: 24622842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
    Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
    Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry of INI1 expression: a new tool for old challenges in CNS and soft tissue pathology.
    Judkins AR
    Adv Anat Pathol; 2007 Sep; 14(5):335-9. PubMed ID: 17717433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tet-Mediated DNA Demethylation Is Required for SWI/SNF-Dependent Chromatin Remodeling and Histone-Modifying Activities That Trigger Expression of the Sp7 Osteoblast Master Gene during Mesenchymal Lineage Commitment.
    Sepulveda H; Villagra A; Montecino M
    Mol Cell Biol; 2017 Oct; 37(20):. PubMed ID: 28784721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic regulation in human melanoma: past and future.
    Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
    Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease.
    Kadoch C; Copeland RA; Keilhack H
    Biochemistry; 2016 Mar; 55(11):1600-14. PubMed ID: 26836503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycomb Repressor Complex 2 in Genomic Instability and Cancer.
    Veneti Z; Gkouskou KK; Eliopoulos AG
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
    Morel D; Almouzni G; Soria JC; Postel-Vinay S
    Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic factors in cancer development: polycomb group proteins.
    Piunti A; Pasini D
    Future Oncol; 2011 Jan; 7(1):57-75. PubMed ID: 21174538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma.
    Manceau G; Letouzé E; Guichard C; Didelot A; Cazes A; Corté H; Fabre E; Pallier K; Imbeaud S; Le Pimpec-Barthes F; Zucman-Rossi J; Laurent-Puig P; Blons H
    Int J Cancer; 2013 May; 132(9):2217-21. PubMed ID: 23047306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INI1-deficient tumors: diagnostic features and molecular genetics.
    Hollmann TJ; Hornick JL
    Am J Surg Pathol; 2011 Oct; 35(10):e47-63. PubMed ID: 21934399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Giant cell tumor of bone: updated molecular pathogenesis and tumor biology.
    Noh BJ; Park YK
    Hum Pathol; 2018 Nov; 81():1-8. PubMed ID: 29944971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations.
    Stockman DL; Curry JL; Torres-Cabala CA; Watson IR; Siroy AE; Bassett RL; Zou L; Patel KP; Luthra R; Davies MA; Wargo JA; Routbort MA; Broaddus RR; Prieto VG; Lazar AJ; Tetzlaff MT
    J Cutan Pathol; 2015 May; 42(5):308-17. PubMed ID: 25754356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.